Shield Therapeutics plc (STX) Ordinary Shares 1.5p

- Add to watchlist
- Create an alert
- This stock can be held in a




2.35p
2.50p
5.80p
£24.48 million
2.26p
2.32p
1.25p
n/a
0.09p (3.83%) Previous:
0.09p
2,704,358
n/a
75,000
Performance
Not available for this stock.
Fundamental data
Year ending: | 31/12/2024 | 31/12/2023 |
---|---|---|
Revenue (£m) | 32.18 | 13.09 |
Profit before tax (£m) | (26.56) | (32.38) |
Adjusted EPS (p): | (3.00) | (5.00) |
P/E ratio | n/a | n/a |
PEG | n/a | n/a |
EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: British pound
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
Shield Therapeutics inks exclusive licence agreement in Japan
22 April 2025 09:03
-
Shield Therapeutics appoints Anders Lundstrom as permanent CEO
27 January 2025 15:40
-
Shield Therapeutics secures $10m investment, announces RetailBook offer
6 December 2024 11:46
-
Audited results for the year ended 31 Dec 2024
24 April 2025 07:06
-
Licence Agreement in Japan for ACCRUFeR®
22 April 2025 07:01
-
Q1 2025 Trading Update
17 April 2025 11:23
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.